TLA Targeted Immunotherapies AB
🇸🇪Sweden
Dose-Evaluation Study of the Efficacy and Safety of TLA Gutâ„¢ Leukapheresis Treatment in Patients With Ulcerative Colitis
Not Applicable
Recruiting
- Conditions
- Ulcerative Colitis (UC)
- Interventions
- Device: TLA Gutâ„¢
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- TLA, Targeted Immunotherapies AB
- Target Recruit Count
- 12
- Registration Number
- NCT04550130
- Locations
- 🇸🇪
Ersta Sjukhus, Medicinkliniken, Stockholm, Sweden
© Copyright 2025. All Rights Reserved by MedPath